Despite significant improvements in ALS model mice achieved by genetic or viral overexpression of IGF-1, to date efficacy studies of recombiant IGF-1 have yeilded positvie results in two human trials while a third trial reported no improvements in muscle strength. This evidence concerns the gene IGF1 and amyotrophic lateral sclerosis.